Olivier Muller

Olivier Muller

Auto-generated profile, based on publicly available information

Olivier Muller

Cardiology Department, Lausanne University Hospital and University of Lausanne, 1005 Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2023 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
PDF file
ISIoannis Skalidis
Ioannis Skalidis
ACAurelien Cagnina
Aurelien Cagnina
WLWongsakorn Luangphiphat
Wongsakorn Luangphiphat
TMThabo Mahendiran
Thabo Mahendiran
OMOlivier Muller
Olivier Muller
SFStephane Fournier
Stephane Fournier
Chat Generative Pre-trained Transformer (ChatGPT) is currently a trending topic worldwide triggering extensive debate about its predictive power, its potential uses, and its wider implications. Recent publications have demonstrated that ChatGPT can correctly answer questions from undergraduate exams such as the United States Medical Licensing Examination. We challenged it to answer questions from a more demanding, post-graduate exam—the European Exam in Core Cardiology (EECC), the final exam for the completion of specialty training in Cardiology in many countries. Our results demonstrate that ChatGPT succeeds in the EECC.

24 March 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SKSimon Kraler
Simon Kraler
FWFlorian A Wenzl
Florian A Wenzl
GGGeorgios Georgiopoulos
Georgios Georgiopoulos
SOSlayman Obeid
Slayman Obeid
LLLuca Liberale
Luca Liberale
TLThomas F. Lüscher
Thomas F. Lüscher
The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and its shedding product [soluble LOX-1 (sLOX-1)] are implicated in atherosclerotic cardiovascular disease (ASCVD) pathogenesis. Herein, we examined the relationship of sLOX-1 with both fatal events and plaque progression in patients with acute coronary syndromes (ACS). Plasma sLOX-1 was assessed at baseline in ACS and chronic coronary syndrome (CCS) patients prospectively recruited in the multicentre SPUM-ACS study, with sex- and age-matched healthy subjects serving as additional controls (n = 2924). Compared with both CCS and controls, ACS patients showed markedly elevated sLOX-1 levels (median, 2.00 and 2.00 vs. 35.08 pg/mL; P < 0.0001) which were independently associated with increased mortality risk over 30-day [tertile (T)3: adjusted hazard ratio (HR), 3.11; 95% confidence interval (CI), 1.44–10.61; P = 0.0055] and 1-year intervals (T3: adjusted HR, 2.04; 95% CI, 1.19–3.92; P = 0.0098). Results remained consistent after adjustment for GRACE 2.0 (T3: adjusted HR, 1.86; 95% CI, 1.04–3.74; P = 0.0391) and were primarily driven by the pronounced relationship of sLOX-1 with cardiovascular mortality at 30 days (T3: adjusted HR, 3.81; 95% CI, 1.62–19.62; P = 0.0036) and at 1 year (T3: adjusted HR, 2.29; 95% CI, 1.19–5.34; P = 0.0148). In ACS patients undergoing serial intracoronary imaging and statin therapy, sLOX-1 dropped significantly in those with coronary plaque regression at 1 year (ΔsLOX-1: −4.64 ± 1.80; P = 0.0057), and showed a good discrimination for predicting plaque progression (area under the curve = 0.74; 95% CI, 0.59–0.86; P = 0.0031). Plasma sLOX-1 levels are increased during ACS and predict fatal events beyond traditional and emerging risk factors. Persistently high sLOX-1 associates with coronary plaque progression in patients with established ASCVD. NCT01000701. Atherosclerotic plaques express high levels of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), with plaque regions particularly prone for instability showing accentuated LOX-1 abundance. The pro-inflammatory milieu within atherosclerotic plaques enhances LOX-1 synthesis, promotes LOX-1 shedding and thus soluble LOX-1 (sLOX-1) release. The turnover of membrane-bound LOX-1 determines plaque composition and thus stability, with systemically circulating sLOX-1 emerging as a novel biomarker reflecting plaque burden and vulnerability. In this multicentre prospective cohort study, we found that plasma levels of sLOX-1 are markedly elevated in patients presenting with acute coronary syndromes (ACS) when compared with both chronic coronary syndrome (CCS) and healthy subjects (CTRL). High sLOX-1 levels were independently associated with a higher multivariable-adjusted 1-year mortality risk following ACS, a finding that remained consistent after controlling for GRACE 2.0. In patients subjected to serial intravascular ultrasound following the index ACS, sLOX-1 dropped markedly in those with coronary plaque regression, while persistently high sLOX-1 levels were associated with plaque progression. §Adjusted for sex, age, ACS type, hs-CRP, history of hypercholesterolaemia, eGFR, LDL-C, and diagnosis of diabetes; †adjusted for sex, age, ACS type, hs-CRP, history of hypercholesterolaemia, eGFR, LDL-C, diagnosis of diabetes, NT-proBNP, and hs-TnT. ADAM, a disintegrin and metalloproteinase; GRACE, Global Registry of Acute Coronary Events; IVUS, intravascular ultrasound; MMP, matrix metalloproteinase; LOX-1, lectin-like oxidized low-density lipoprotein receptor-1; sLOX-1, soluble LOX-1.

26 August 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
FWFlorian A Wenzl
Florian A Wenzl
FBFrancesco Bruno
Francesco Bruno
SKSimon Kraler
Simon Kraler
RKRoland Klingenberg
Roland Klingenberg
AAAlexander Akhmedov
Alexander Akhmedov
TLThomas F. Lüscher
Thomas F. Lüscher
Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. This study examined the relationship of circulating DPP3 (cDPP3) with cardiogenic shock (CS) and mortality in patients presenting with acute coronary syndromes (ACS). Plasma cDPP3 levels were assessed at baseline and 12–24 h after presentation in patients with ACS prospectively enrolled into the multi-centre SPUM-ACS study (n = 4787). Circulating DPP3 levels were associated with in-hospital CS when accounting for established risk factors including the ORBI risk score [per log-2 increase, hazard ratio (HR) 1.38, 95% confidence interval (CI) 1.05–1.82, P = .021]. High cDPP3 was an independent predictor of mortality at 30 days (HR 1.87, 95% CI 1.36–2.58, P < .001) and at one year (HR 1.61, 95% CI 1.28–2.02, P < .001) after adjustment for established risk factors and the GRACE 2.0 score. Compared to values within the normal range, persistently elevated cDPP3 levels at 12–24 h were associated with 13.4-fold increased 30-day mortality risk (HR 13.42, 95% CI 4.86–37.09, P < .001) and 5.8-fold increased 1-year mortality risk (HR 5.79, 95% CI 2.70–12.42, P < .001). Results were consistent across various patient subgroups. This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment. Circulating dipeptidyl peptidase 3 (cDPP3) was identified as a novel marker of cardiogenic shock (CS) and increased mortality risk in patients with acute coronary syndromes (ACS). Upon ischaemic cell death, the intracellular aminopeptidase DPP3 is released in the circulation where it cleaves angiotensin II (ATII) and exerts negative inotropic effects on the left ventricle. Circulating DPP3 levels were measured at presentation and after 12–24 h in patients enrolled into the multi-centre prospective SPUM-ACS study. High baseline levels of cDPP3 were independently associated with in-hospital CS, mortality risk at 30 days, and mortality risk at 1 year beyond established risk factors. Patients with persistently high cDPP3 levels at 12–24 h displayed substantially increased 30-day and 1-year mortality risk, whereas normalization of initially high cDDP3 levels was associated with a decrease in mortality risk. In a subcohort of patients undergoing cardiac magnetic resonance imaging (MRI), cDPP3 trajectories were associated with infarct size at 30 days of follow-up. Circulating DPP3 provides prognostic information beyond established risk factors in patients with ACS.

13 September 2021 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
APAnna Giulia Pavon
Anna Giulia Pavon
DADimitri Arangalage
Dimitri Arangalage
PPPatrizio Pascale
Patrizio Pascale
SHSarah Hugelshofer
Sarah Hugelshofer
TRTobias Rutz
Tobias Rutz
PMPierre Monney
Pierre Monney
We aimed to evaluate the relationship between mitral annular disjunction (MAD) severity and myocardial interstitial fibrosis at the left ventricular (LV) base in patients with mitral valve prolapse (MVP), and to assess the association between severity of interstitial fibrosis and the occurrence of ventricular arrhythmic events. In MVP, MAD has been associated with myocardial replacement fibrosis and arrhythmia, but the importance of interstitial fibrosis remains unknown. In this retrospective study, 30 patients with MVP and MAD (MVP–MAD) underwent cardiovascular magnetic resonance (CMR) with assessment of MAD length, late gadolinium enhancement (LGE), and basal segments myocardial extracellular volume (ECVsyn). The control group included 14 patients with mitral regurgitation (MR) but no MAD (MR-NoMAD) and 10 patients with normal CMR (NoMR-NoMAD). Fifteen MVP–MAD patients underwent 24 h-Holter monitoring. LGE was observed in 47% of MVP–MAD patients and was absent in all controls. ECVsyn was higher in MVP–MAD (30 ± 3% vs 24 ± 3% MR-NoMAD, p < 0.001 and vs 24 ± 2% NoMR-NoMAD, p < 0.001), even in MVP–MAD patients without LGE (29 ± 3% vs 24 ± 3%, p < 0.001 and vs 24 ± 2%, p < 0.001, respectively). MAD length correlated with ECVsyn (rho = 0.61, p < 0.001), but not with LGE extent. Four patients had history of out-of-hospital cardiac arrest; LGE and ECVsyn were equally performant to identify those high-risk patients, area under the receiver operating characteristic (ROC) curve 0.81 vs 0.83, p = 0.84). Among patients with Holter, 87% had complex ventricular arrhythmia. ECVsyn was above the cut-off value in all while only 53% had LGE. Increase in ECVsyn, a marker of interstitial fibrosis, occurs in MVP–MAD even in the absence of LGE, and was correlated with MAD length and increased risk of out-of-hospital cardiac arrest. ECV should be includedin the CMR examination of MVP patients in an effort to better assess fibrous remodelling as it may provide additional value beyond the assessment of LGE in the arrhythmic risk stratification.

30 August 2017 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
SFStephane Fournier
Stephane Fournier
LILea Iten
Lea Iten
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
OBOlivier Boulat
Olivier Boulat
DBDaniel Bardy
Daniel Bardy
OMOlivier Muller
Olivier Muller

11 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SFStephane Fournier
Stephane Fournier
PTPatrick Taffé
Patrick Taffé
DRDragana Radovanovic
Dragana Radovanovic
EEErik Von Elm
Erik Von Elm
BMBeata Morawiec
Beata Morawiec
OMOlivier Muller
Olivier Muller
Different studies have shown circadian variation of ischemic burden among patients with ST-Elevation Myocardial Infarction (STEMI), but with controversial results. The aim of this study was to analyze circadian variation of myocardial infarction size and in-hospital mortality in a large multicenter registry. This retrospective, registry-based study was based on data from AMIS Plus, a large multicenter Swiss registry of patients who suffered myocardial infarction between 1999 and 2013. Peak creatine kinase (CK) was used as a proxy measure for myocardial infarction size. Associations between peak CK, in-hospital mortality, and the time of day at symptom onset were modelled using polynomial-harmonic regression methods. 6,223 STEMI patients were admitted to 82 acute-care hospitals in Switzerland and treated with primary angioplasty within six hours of symptom onset. Only the 24-hour harmonic was significantly associated with peak CK (p = 0.0001). The maximum average peak CK value (2,315 U/L) was for patients with symptom onset at 23:00, whereas the minimum average (2,017 U/L) was for onset at 11:00. The amplitude of variation was 298 U/L. In addition, no correlation was observed between ischemic time and circadian peak CK variation. Of the 6,223 patients, 223 (3.58%) died during index hospitalization. Remarkably, only the 24-hour harmonic was significantly associated with in-hospital mortality. The risk of death from STEMI was highest for patients with symptom onset at 00:00 and lowest for those with onset at 12:00. As a part of this first large study of STEMI patients treated with primary angioplasty in Swiss hospitals, investigations confirmed a circadian pattern to both peak CK and in-hospital mortality which were independent of total ischemic time. Accordingly, this study proposes that symptom onset time be incorporated as a prognosis factor in patients with myocardial infarction.